Affinage

CCNA2

Cyclin-A2 · UniProt P20248

Length
432 aa
Mass
48.6 kDa
Annotated
2026-06-09
55 papers in source corpus 25 papers cited in narrative 26 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 6/6 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

CCNA2 (Cyclin A2) is a cell cycle regulator that activates CDK2 to drive G1/S and G2/M progression, and its loss in cancer cells impairs cell cycle transit and induces apoptosis (PMID:30464611). The CCNA2–CDK2 complex executes both canonical proliferative functions and non-canonical signaling: it phosphorylates the AXIN1 complex to promote ubiquitination-dependent β-catenin degradation and WNT pathway inhibition during AT2 cell differentiation in lung adenocarcinoma (PMID:38704137), and the CCNA2/CDK2 axis is a downstream effector of ROBO1-mediated control of S-phase progression in pancreatic cancer (PMID:33714986). Beyond proliferation, CCNA2 sets cellular lifespan: p53-responsive miRNAs (miR-124, miR-29) repress CCNA2, its silencing triggers senescence, and CCNA2 overexpression delays senescence even in p21-deficient cells, defining a p53/miRNA/CCNA2 axis that operates independently of canonical p53/p21 control (PMID:30848072). CCNA2 also carries a non-cell-cycle role in mature hippocampal neurons, where it colocalizes with dendritic rRNA and is required for neuronal ribostasis—its ablation causes rRNA granule accumulation and synaptic loss (PMID:30579783). CCNA2 transcription is directly activated by E2F1 (PMID:34366326), CREB1 (PMID:35777504), CDCA7 (PMID:34737951), and MYC (PMID:41690656) binding at its promoter, controlled by KDM4B/KDM4A histone demethylase occupancy (PMID:33917420) and H3K18 lactylation at its locus (PMID:41854933), and is post-transcriptionally repressed by multiple 3'UTR-targeting miRNAs including miR-381-3p, miR-22, and miR-152 (PMID:30138038, PMID:27738335, PMID:36310381). CCNA2 additionally mediates trophoblast migration via RhoA-ROCK signaling (PMID:31087423) and drives pro-inflammatory M1 macrophage polarization that promotes hepatocyte lipid accumulation through paracrine signaling (PMID:42235667).

Mechanistic history

Synthesis pass · year-by-year structured walk · 10 steps
  1. 2013 Medium

    Established that CCNA2 is a direct miRNA target whose derepression drives aberrant S-phase entry, linking its dosage to inappropriate cell cycle re-entry in neurons.

    Evidence miR-124 manipulation and cell cycle flow cytometry in Huntington's disease striatal cells and R6/2 mouse model

    PMID:23796713

    Open questions at the time
    • Direct 3'UTR luciferase confirmation of miR-124 targeting not detailed
    • Mechanism connecting S-phase entry to neuronal pathology unresolved
  2. 2018 Medium

    Defined CCNA2 as a driver of both G1/S and G2/M transitions whose loss couples cell cycle arrest to apoptosis, framing it as a proliferative dependency in cancer.

    Evidence siRNA knockdown with cell cycle and apoptosis flow cytometry in colorectal cancer cells

    PMID:30464611

    Open questions at the time
    • CDK partner not directly demonstrated in this context
    • Apoptotic effector pathway not mapped
  3. 2018 High

    Revealed a non-canonical CCNA2 function in post-mitotic neurons, showing it is required for dendritic ribostasis rather than cell division.

    Evidence Conditional knockout mouse, immunohistochemistry, electron microscopy, and rRNA colocalization

    PMID:30579783

    Open questions at the time
    • Molecular mechanism linking CCNA2 to rRNA granule clearance unknown
    • No identified CCNA2 partner in neuronal dendrites
  4. 2019 High

    Placed CCNA2 as the effector node of a senescence-controlling pathway operating independently of p21, redefining its role from pure proliferation to lifespan regulation.

    Evidence miRNA/mRNA microarray, luciferase reporter, SA-β-gal assays, and p21-deficient cell experiments

    PMID:30848072

    Open questions at the time
    • Downstream substrates of CCNA2 mediating senescence delay not identified
    • Relationship to canonical CDK2 activity in this context unresolved
  5. 2019 Medium

    Extended CCNA2 function to cell motility, implicating it in trophoblast migration via RhoA-ROCK alongside p53-pathway control of proliferation and apoptosis.

    Evidence siRNA knockdown, overexpression, migration/proliferation/apoptosis assays in HTR8/SVneo cells and villi explants

    PMID:31087423

    Open questions at the time
    • Direct link between CCNA2 and RhoA-ROCK activation not biochemically established
    • Whether migration role requires CDK2 unknown
  6. 2022 Medium

    Mapped the upstream transcriptional control of CCNA2, identifying multiple direct activators converging on its promoter to set proliferative output.

    Evidence Luciferase reporter, ChIP, and rescue experiments for E2F1, CREB1, CDCA7, and MYC across cancer and myoblast models

    PMID:34366326 PMID:34737951 PMID:35777504 PMID:41690656

    Open questions at the time
    • Combinatorial logic among activators at the promoter not resolved
    • Cell-type specificity of each factor's contribution unclear
  7. 2021 Medium

    Established epigenetic control of CCNA2 transcription through histone demethylase occupancy with built-in paralog compensation.

    Evidence RNAi screen and ChIP showing KDM4B and compensatory KDM4A occupancy at the CCNA2 promoter in rhabdomyosarcoma

    PMID:33917420

    Open questions at the time
    • Histone mark altered at the CCNA2 promoter not directly measured
    • Mechanism of KDM4A compensatory recruitment unknown
  8. 2024 Medium

    Identified a non-cell-cycle signaling output of the CCNA2-CDK2 complex, phosphorylating the AXIN1 complex to degrade β-catenin and gate WNT-dependent cancer stem cell differentiation.

    Evidence Co-IP, phosphorylation assay, single-cell sequencing, and CCNA2 inhibition in lung adenocarcinoma

    PMID:38704137

    Open questions at the time
    • Direct AXIN1 phosphosite not mapped by mutagenesis
    • Reconstitution of the kinase reaction not performed
  9. 2026 Medium

    Showed that metabolite-driven epigenetic signaling controls CCNA2 transcription, with H3K18 lactylation at its locus serving as a regulatory input.

    Evidence CUT&Tag, ChIP, RIP, and ubiquitination assays linking circBARD1-ENO1-lactate to CCNA2 lactylation in bladder cancer

    PMID:41854933

    Open questions at the time
    • Reader of H3K18 lactylation at the CCNA2 locus not identified
    • Quantitative contribution of lactylation versus transcription factors unresolved
  10. 2026 Medium

    Expanded CCNA2 function to immune-metabolic crosstalk, showing it drives pro-inflammatory macrophage polarization that promotes hepatocyte lipid accumulation by paracrine signaling.

    Evidence siRNA knockdown/re-expression, conditioned medium transfer, lipid and cytokine assays, and in vivo mouse model

    PMID:42235667

    Open questions at the time
    • Paracrine mediator induced by CCNA2 not identified
    • Mechanism linking CCNA2 to M1 polarization unknown

Open questions

Synthesis pass · forward-looking unresolved questions
  • How CCNA2's distinct cell-cycle and non-canonical functions (WNT signaling, neuronal ribostasis, macrophage polarization) are partitioned and whether they all depend on CDK2 catalytic activity remains unresolved.
  • No unified substrate map distinguishing canonical from non-canonical functions
  • CDK2-dependence of non-cell-cycle roles untested
  • No structural model of context-specific CCNA2 complexes

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0098772 molecular function regulator activity 2 GO:0140096 catalytic activity, acting on a protein 1
Localization
GO:0005634 nucleus 2
Pathway
R-HSA-74160 Gene expression (Transcription) 4 R-HSA-1640170 Cell Cycle 3 R-HSA-162582 Signal Transduction 2 R-HSA-8953897 Cellular responses to stimuli 1
Partners
AXIN1CDCA5CDK2PKMYT1
Complex memberships
CCNA2-CDK2 complex

Evidence

Reading pass · 26 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2024 CCNA2 binding to CDK2 phosphorylates the AXIN1 complex, which induces ubiquitination-dependent degradation of β-catenin and inhibits the WNT signaling pathway, thereby promoting AT2 cell differentiation into AT2-like cancer stem cells in lung adenocarcinoma. Co-immunoprecipitation, phosphorylation assay, western blot, single-cell sequencing analysis, CCNA2 inhibition experiments Cancer letters Medium 38704137
2019 CCNA2 promotes trophoblast migration via the RhoA-ROCK signaling pathway, and promotes trophoblast proliferation while inhibiting apoptosis via the p53 pathway; CCNA2 knockdown impairs these functions in HTR8/SVneo cells. siRNA knockdown, overexpression, migration assay, proliferation assay, apoptosis assay, western blot in HTR8/SVneo cells and ex vivo villi explant culture American journal of reproductive immunology Medium 31087423
2018 CCNA2 regulates cell cycle progression by promoting G1/S and G2/M transitions; knockdown of CCNA2 in colorectal cancer cells impairs cell cycle progression and induces apoptosis. siRNA knockdown, cell cycle analysis by flow cytometry, apoptosis assay, cell growth assay Cancer management and research Medium 30464611
2018 CCNA2 functions in a non-canonical, non-cell-cycle role in mature hippocampal neurons: cyclin A2 colocalizes with dendritic rRNA, and its ablation results in decreased synaptic density and accumulation of rRNA granules in dendrite shafts, indicating a role in neuronal ribostasis. Conditional knockout mouse model, immunohistochemistry, electron microscopy, confocal colocalization with rRNA markers The American journal of pathology High 30579783
2019 The p53/miRNAs/CCNA2 pathway regulates cellular senescence independently of the canonical p53/p21 pathway: p53-responsive miRNAs (miR-124, miR-29) target CCNA2, silencing of CCNA2 triggers senescence, and CCNA2 overexpression delays senescence and reverses miRNA-induced senescence even in p21-deficient cells. miRNA/mRNA microarray, luciferase reporter assay, senescence assays (SA-β-gal), overexpression and knockdown, p21-deficient cell experiments Aging cell High 30848072
2013 MicroRNA-124 directly targets CCNA2, and decreased miR-124 leads to increased CCNA2 expression and increased S-phase fraction in Huntington's disease striatal cells; exogenous manipulation of either miR-124 or CCNA2 alters cell cycle distribution. qRT-PCR, cell cycle analysis (flow cytometry), miR-124 overexpression/inhibition, CCNA2 overexpression/knockdown, validated in HD mouse model (R6/2) Biochemical and biophysical research communications Medium 23796713
2022 E2F1 transcription factor directly binds the CCNA2 promoter at position +677 and transcriptionally activates CCNA2 expression; E2F1 knockdown reduces CCNA2 expression and decreases TNBC cell proliferation, invasion, and migration. Luciferase reporter assay, ChIP, rescue experiments, bioinformatics correlation analysis Cancer biomarkers Medium 34366326
2021 CREB1 directly binds the proximal promoter region of CCNA2 and transcriptionally activates it, promoting S-phase DNA synthesis and G2 cell division in bovine myoblasts. Dual luciferase reporter assay, promoter binding assay, CREB1 overexpression/knockdown, cell cycle analysis International journal of biological macromolecules Medium 35777504
2021 CDCA7 directly binds to the CCNA2 promoter and upregulates its expression in esophageal squamous cell carcinoma; knockdown of CCNA2 reverses the malignant proliferative phenotype induced by CDCA7 overexpression. ChIP assay, luciferase reporter assay, rescue experiment, western blot, cell proliferation and colony formation assays Frontiers in oncology Medium 34737951
2021 ROBO1 inhibits pancreatic cancer cell proliferation and S-phase progression via the CCNA2/CDK2 axis; YY1 directly binds the ROBO1 promoter to promote its transcription, establishing a YY1-ROBO1-CCNA2-CDK2 axis. Luciferase reporter assay, ChIP, EMSA, overexpression experiments in vitro and xenograft in vivo Oncogene Medium 33714986
2021 KDM4B histone demethylase is bound at the promoter regions of CCNA2 (and CDK6) and regulates their transcription to control cell cycle progression in rhabdomyosarcoma; sustained KDM4B knockdown leads to compensatory KDM4A recruitment to the same CCNA2 and CDK6 promoter regions. RNAi screening, ChIP showing KDM4B and KDM4A promoter occupancy at CCNA2, cell cycle analysis, rescue/recovery experiments Cancers Medium 33917420
2021 PKMYT1 physically binds CCNA2 (shown by co-immunoprecipitation) and PKMYT1 knockdown reduces CCNA2 expression, inhibiting proliferation, migration, invasion, and EMT in oral squamous cell carcinoma cells. Co-immunoprecipitation, siRNA knockdown, western blot, proliferation/migration/invasion assays, wound healing assay Oncology letters Medium 35069872
2022 6-Methoxyflavone induces S-phase arrest in HeLa cells via the CCNA2/CDK2/p21CIP1 signaling pathway; molecular docking showed that the combination of CDK2 and CCNA2 enhances compound binding affinity to CDK2. Cell cycle flow cytometry, western blot, qPCR, molecular docking, transcriptome sequencing Bioengineered Low 35246013
2021 Tanshinone IIA suppresses lung adenocarcinoma cell cycle progression by downregulating the CCNA2-CDK2 complex and AURKA/PLK1 pathway, inducing G1/S arrest and apoptosis. Western blot, flow cytometry (cell cycle and apoptosis), MTT/clonogenic assay, molecular docking Scientific reports Low 34880385
2018 miR-381-3p directly targets the 3'UTR of CCNA2; inhibition of CCNA2 by miR-381-3p participates in proliferation regulation together with CDK6 and also modulates EMT progression via the ROCK/AKT/β-catenin/SNAIL pathway in bladder cancer. Dual-luciferase reporter assay, bioinformatics, siRNA knockdown, in vitro proliferation and migration assays, in vivo tumor models FASEB journal Medium 30138038
2016 FXR-regulated miR-22 directly represses CCNA2 in hepatocellular carcinoma; WA induces miR-22 expression leading to CCNA2 repression and cell proliferation arrest; FXR knockdown or miR-22 silencing reverses CCNA2 repression and restores proliferation. FXR/miR-22/CCNA2 expression in clinical samples, miR-22 manipulation (overexpression/silencing), FXR knockdown, in vivo xenograft model Oncotarget Medium 27738335
2025 6PGD binds ALKBH5 and inhibits its m6A demethylase activity through a non-metabolic function, increasing m6A modification and stability of MDM2 mRNA, decreasing p53 protein stability, which subsequently activates CCNA2 expression and promotes colorectal cancer tumor growth and metastasis. Co-immunoprecipitation, m6A modification assay, mRNA stability assay, western blot, siRNA knockdown, in vitro and in vivo tumor models Journal of experimental & clinical cancer research Medium 40611205
2025 CDCA5 physically interacts with CCNA2 (shown by co-immunoprecipitation) and regulates its expression in NSCLC cells; berberine treatment reduces both CDCA5 and CCNA2 levels, and overexpression of either attenuates berberine's inhibitory effects on NSCLC. Co-immunoprecipitation, qRT-PCR, western blot, overexpression rescue assay, in vivo xenograft model Journal of natural medicines Low 40155519
2026 H3K18 lactylation at the CCNA2 locus drives its transcription in bladder cancer; circBARD1 promotes ENO1 ubiquitination and FBXW7-mediated degradation, which reduces intracellular lactate and H3K18 lactylation, thereby suppressing CCNA2 transcription. CUT&Tag, ChIP assay, RNA immunoprecipitation (RIP), Co-immunoprecipitation, ubiquitination assay, gain-of-function experiments Cellular oncology Medium 41854933
2022 ADM overexpression inhibits miR-152, which normally directly targets and suppresses CCNA2; the ADM/miR-152/CCNA2 axis promotes cell cycle progression (increased G2/M phase) and reduces p53, p21WAF1, and p16INK4A in human dental pulp stem cells, conferring antisenescence effects. Luciferase reporter assay, transfection with miR-152 mimic/antagomir, western blot, flow cytometry (cell cycle), transcriptome analysis Cell cycle Medium 36310381
2019 miR-219a-5p upregulation in neuronal injury models inhibits CCNA2 and CACUL1 expression, activating akt/Foxo3a and p53/Bcl-2 signaling pathways and increasing cleaved caspase-3, thereby inducing neuronal apoptosis. TaqMan Low Density Array, RT-qPCR validation, neuronal cell injury model, western blot for signaling pathway proteins Journal of neurochemistry Low 31077370
2018 Sevoflurane exposure upregulates miR-19-3p, which post-transcriptionally inhibits CCNA2 protein translation in neurons; intracranial injection of anti-miR-19-3p AAV reversed SEVO-induced impairment of neuron proliferation and learning/memory in neonatal rats. Luciferase reporter assay, western blot, AAV-mediated in vivo anti-miRNA injection, behavioral testing (Morris water maze, Plus-Maze) Aging Medium 30540563
2025 MEIOC downregulates CCNA2 protein expression during the mitosis-to-meiosis transition in mouse oogenesis, contributing to repression of the mitotic G1/S cyclin program prior to meiotic entry. Cell cycle transcriptomics, cell cycle-associated protein expression analysis, proliferation assays, MEIOC loss-of-function mouse model bioRxiv (preprint)preprint Medium
2025 GSK6853 (BRPF1 inhibitor) suppresses CCNA2 expression via inhibition of the JAK2/STAT3 signaling pathway, inducing G0/G1 cell cycle arrest and apoptosis in NSCLC cells. RNA sequencing, western blot validating JAK2/STAT3/CCNA2 protein levels, flow cytometry (cell cycle and apoptosis), CCK-8 and colony formation assays Investigational new drugs Low 41160097
2026 MYC directly transcriptionally activates CCNA2 (and KPNA2) in melanoma; kojic acid does not alter MYC expression but impairs MYC promoter binding and transcriptional activation of CCNA2, reducing melanoma proliferation. Transcriptomic profiling, ChIP showing reduced MYC binding at CCNA2 promoter after kojic acid treatment, xenograft in vivo model, single-cell analysis Gene Medium 41690656
2026 CCNA2 expression in macrophages is upregulated by dimethyl phosphate and promotes a pro-inflammatory M1-like macrophage phenotype; CCNA2-expressing macrophage conditioned medium induces lipid accumulation in hepatocytes via paracrine signaling, and CCNA2 silencing attenuates both macrophage polarization and hepatocyte lipid accumulation. siRNA knockdown and re-expression in macrophages, conditioned medium transfer to hepatocytes, lipid accumulation assay, cytokine secretion assay, in vivo mouse model Environmental pollution Medium 42235667

Source papers

Stage 0 corpus · 55 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2018 CCNA2 acts as a novel biomarker in regulating the growth and apoptosis of colorectal cancer. Cancer management and research 81 30464611
2019 The p53/miRNAs/Ccna2 pathway serves as a novel regulator of cellular senescence: Complement of the canonical p53/p21 pathway. Aging cell 64 30848072
2018 Dual regulatory role of CCNA2 in modulating CDK6 and MET-mediated cell-cycle pathway and EMT progression is blocked by miR-381-3p in bladder cancer. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 57 30138038
2022 CCNA2 as an Immunological Biomarker Encompassing Tumor Microenvironment and Therapeutic Response in Multiple Cancer Types. Oxidative medicine and cellular longevity 45 35401923
2017 CCNA2 facilitates epithelial-to-mesenchymal transition via the integrin αvβ3 signaling in NSCLC. International journal of clinical and experimental pathology 42 31966683
2016 Waltonitone inhibits proliferation of hepatoma cells and tumorigenesis via FXR-miR-22-CCNA2 signaling pathway. Oncotarget 41 27738335
2019 MiR-219-5p suppresses cell proliferation and cell cycle progression in esophageal squamous cell carcinoma by targeting CCNA2. Cellular & molecular biology letters 39 30766610
2021 Tanshinone IIA suppresses the progression of lung adenocarcinoma through regulating CCNA2-CDK2 complex and AURKA/PLK1 pathway. Scientific reports 38 34880385
2019 Downregulation of CCNA2 disturbs trophoblast migration, proliferation, and apoptosis during the pathogenesis of recurrent miscarriage. American journal of reproductive immunology (New York, N.Y. : 1989) 38 31087423
2013 MicroRNA-124 targets CCNA2 and regulates cell cycle in STHdh(Q111)/Hdh(Q111) cells. Biochemical and biophysical research communications 34 23796713
2022 E2F1 transcriptionally regulates CCNA2 expression to promote triple negative breast cancer tumorigenicity. Cancer biomarkers : section A of Disease markers 28 34366326
2020 MiR-29c-3p Suppresses the Migration, Invasion and Cell Cycle in Esophageal Carcinoma via CCNA2/p53 Axis. Frontiers in bioengineering and biotechnology 27 32154226
2020 miR‑508‑3p suppresses the development of ovarian carcinoma by targeting CCNA2 and MMP7. International journal of oncology 27 32377701
2019 Screening the expression of several miRNAs from TaqMan Low Density Array in traumatic brain injury: miR-219a-5p regulates neuronal apoptosis by modulating CCNA2 and CACUL1. Journal of neurochemistry 26 31077370
2020 Long noncoding RNA DNAH17-AS1 promotes tumorigenesis and metastasis of non-small cell lung cancer via regulating miR-877-5p/CCNA2 pathway. Biochemical and biophysical research communications 23 32981678
2021 Roundabout homolog 1 inhibits proliferation via the YY1-ROBO1-CCNA2-CDK2 axis in human pancreatic cancer. Oncogene 22 33714986
2024 Smoking-induced CCNA2 expression promotes lung adenocarcinoma tumorigenesis by boosting AT2/AT2-like cell differentiation. Cancer letters 19 38704137
2022 CREB1 promotes proliferation and differentiation by mediating the transcription of CCNA2 and MYOG in bovine myoblasts. International journal of biological macromolecules 19 35777504
2021 CDCA7 Facilitates Tumor Progression by Directly Regulating CCNA2 Expression in Esophageal Squamous Cell Carcinoma. Frontiers in oncology 19 34737951
2020 Pharmacogenomic Analysis Reveals CCNA2 as a Predictive Biomarker of Sensitivity to Polo-Like Kinase I Inhibitor in Gastric Cancer. Cancers 19 32486290
2021 Integrated Profiling Identifies CCNA2 as a Potential Biomarker of Immunotherapy in Breast Cancer. OncoTargets and therapy 17 33859479
2018 Sevoflurane impairs learning and memory of the developing brain through post-transcriptional inhibition of CCNA2 via microRNA-19-3p. Aging 17 30540563
2020 Hsa_circ_0003732 promotes osteosarcoma cells proliferation via miR-545/CCNA2 axis. Bioscience reports 16 32537647
2016 Mmu-miR-125b overexpression suppresses NO production in activated macrophages by targeting eEF2K and CCNA2. BMC cancer 16 27020049
2024 CCNA2 and NEK2 regulate glioblastoma progression by targeting the cell cycle. Oncology letters 13 38516683
2021 PKMYT1 regulates the proliferation and epithelial-mesenchymal transition of oral squamous cell carcinoma cells by targeting CCNA2. Oncology letters 13 35069872
2024 CDK1 and CCNA2 play important roles in oral squamous cell carcinoma. Medicine 12 38640322
2022 The noncoding RNA CcnA modulates the master cell cycle regulators CtrA and GcrA in Caulobacter crescentus. PLoS biology 11 35192605
2021 Silencing of LncRNA AFAP1-AS1 Inhibits Cell Proliferation in Oral Squamous Cancer by Suppressing CCNA2. Cancer management and research 11 34703311
2022 6-Methoxyflavone induces S-phase arrest through the CCNA2/CDK2/p21CIP1 signaling pathway in HeLa cells. Bioengineered 9 35246013
2022 Overexpression of adrenomedullin (ADM) alleviates the senescence of human dental pulp stem cells by regulating the miR-152/CCNA2 pathway. Cell cycle (Georgetown, Tex.) 9 36310381
2022 Coevolution of HTLV-1-HBZ, Tax, and proviral load with host IRF-1 and CCNA-2 in HAM/TSP patients. Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases 8 35835355
2016 A prospective study of two isothermal amplification assays compared with real-time PCR, CCNA and toxigenic culture for the diagnosis of Clostridium difficile infection. BMC microbiology 8 26868647
2021 Role for the Histone Demethylase KDM4B in Rhabdomyosarcoma via CDK6 and CCNA2: Compensation by KDM4A and Apoptotic Response of Targeting Both KDM4B and KDM4A. Cancers 7 33917420
2023 BUB1, BUB1B, CCNA2, and CDCA8, along with miR-524-5p, as clinically relevant biomarkers for the diagnosis and treatment of endometrial carcinoma. BMC cancer 5 37853361
2022 ECPPF (E2F1, CCNA2, POLE, PPP2R1A, FBXW7) stratification: Profiling high-risk subtypes of histomorphologically low-risk and treatment-insensitive endometrioid endometrial cancer. PloS one 5 36454788
2021 Muse Cells Have Higher Stress Tolerance than Adipose Stem Cells due to the Overexpression of the CCNA2 Gene. Stem cells and development 5 34486391
2011 Identification of single nucleotide polymorphisms in the CCNA2 gene and its association with wool density in Rex rabbits. Genetics and molecular research : GMR 5 22095474
2025 Berberine diminishes the malignant progression of non-small cell lung cancer cells by targeting CDCA5 and CCNA2. Journal of natural medicines 4 40155519
2018 CCNA2 Ablation in Aged Mice Results in Abnormal rRNA Granule Accumulation in Hippocampus. The American journal of pathology 4 30579783
2024 Antihyperlipidemic drug rosuvastatin suppressed tumor progression and potentiated chemosensitivity by downregulating CCNA2 in lung adenocarcinoma. Journal of chemotherapy (Florence, Italy) 3 38288951
2023 Hsa_Circ_0104206 is An Oncogenic circRNA in Colon Cancer by Targeting Mir-188-3p/CCNA2 Axis. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 2 37276868
2026 Metformin Inhibits the Development of Lung Adenocarcinoma by Regulating the Expression of CCNA2 via E2F1. Combinatorial chemistry & high throughput screening 1 40183277
2025 Exploring the regulatory mechanism of CCNA2 in colorectal cancer: Insights from multiomics and experimental analysis. The Journal of biological chemistry 1 40345591
2025 The non-metabolic function of 6PGD coordinates CCNA2 and HMGA2 expression to drive colorectal cancer progression and drug response. Journal of experimental & clinical cancer research : CR 1 40611205
2026 Kojic acid inhibits melanoma progression by targeting the MYC-CCNA2/KPNA2 axis. Gene 0 41690656
2026 CircBARD1 suppresses tumor progression driven by H3K18 lactylation-CCNA2 axis in human bladder cancer. Cellular oncology (Dordrecht, Netherlands) 0 41854933
2026 CCNA2, MAD2L1, AURKA, and PTTG1 promote proliferation and migration in hepatocellular carcinoma. BMC gastroenterology 0 42210102
2026 Integrative epidemiological and experimental evidence implicates CCNA2-associated macrophage-hepatocyte crosstalk in dimethyl phosphate exposure-associated NAFLD. Environmental pollution (Barking, Essex : 1987) 0 42235667
2025 The role of cyclin dependent kinase molecules in the pathogenesis and immune cell infiltration of TNBC in silicosis: Based on core stem cell related genes TPX2 and CCNA2. International journal of biological macromolecules 0 40037461
2025 CCNA2 and CCND2 Are Differentially Involved in β-Cell Proliferation in Perinatal Japanese Autopsied Individuals. The Journal of clinical endocrinology and metabolism 0 40411825
2025 Investigating the molecular mechanisms, drug prediction, and validation of CCNA2 and MAD2L1 in esophageal squamous cell carcinoma based on bioinformatics. BMC medical genomics 0 40598454
2025 Bioinformatics, machine learning, and functional validation reveal CCNA2 as a key target of Ammopiptanthus nanus against rheumatoid arthritis. International journal of biological macromolecules 0 40915462
2025 CCNA2 and CCNB3 as Early Potential Molecular Candidates of Oocyte Maturation in Cumulus-Oophorous Complex Cells from Follicular Fluid. Diagnostics (Basel, Switzerland) 0 41153330
2025 BRPF1 inhibitor GSK6853 inhibits NSCLC cell proliferation via the JAK2/STAT3/CCNA2 axis to induce cell cycle arrest. Investigational new drugs 0 41160097

Missed literature

Know a paper Affinage missed for CCNA2? Flag it for the maintainers and the community.

No submissions yet.